Ind Swift Laboratories Quarterly Results for Trading Insights
In Mar 2026, Ind Swift Laboratories (INDSWFTLAB) reported revenue ₹172 Cr and net profit ₹15 Cr — revenue -52.1% YoY. View INDSWFTLAB 52-week performance for the annual high/low range and current price position.
INDSWFTLAB Quarterly Results — Revenue, Profit & EPS Highlights
Ind Swift Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit INDSWFTLAB share price.
- Revenue of ₹172 Cr in Mar 2026 (-13.6% vs Jun 2026, -52.1% vs Mar 2025)
- Net Profit of ₹15 Cr in Mar 2026 (-40.0% vs Jun 2026, -93.2% vs Mar 2025)
- EBITDA of ₹18 Cr in Mar 2026 (-56.1% vs Jun 2026)
- Operating Margin of 9.0% in Mar 2026 (-8.0pp vs Jun 2026)
- Earnings Per Share of ₹1.81 in Mar 2026 (-36.3% vs Jun 2026)
Ind Swift Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INDSWFTLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 172 | 199 | 171 | 359 | 167 | -13.6% | -52.1% |
| Net Profit (₹ Cr) | 15 | 25 | 8 | 222 | 9 | - | - |
| EBITDA (₹ Cr) | 18 | 41 | 19 | 211 | 18 | - | - |
| EPS (₹) | 1.81 | 2.84 | 1.00 | 32.96 | 1.28 | - | - |
| Operating Margin (%) | 9.0% | 17.0% | 1.0% | -7.0% | 2.0% | - | - |
INDSWFTLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Ind Swift Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse Ind Swift Laboratories ownership structure to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INDSWFTLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Ind Swift Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores